| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcriptsGrowing unme...
-SEC Filing
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...
Goldman Sachs analyst Salveen Richter initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announc...
Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $...